Ceramides can be delivered to cultured cells without solvents in the form of complexes with cholesteryl phosphocholine. We have analysed the delivery of three different radiolabeled D-erythro-ceramides (C6-Cer, C10-Cer and C16-Cer) to HeLa cells, and followed their metabolism as well as the cell viability. We found that all three ceramides were successfully taken up by HeLa cells when complexed to CholPC in an equimolar ratio, and show that the ceramides show different rates of cellular uptake and metabolic fate. The C6-Cer had the highest incorporation rate, followed by C10-Cer and C16-Cer, respectively. The subsequent effect on cell viability strongly correlated with the rate of incorporation, where C6-Cer had the strongest apoptotic effects. Low-dose (1 μM) treatment with C6-Cer favoured conversion of the precursor to sphingomyelin, whereas higher concentrations (25-100 μM) yielded increased conversion to C6-glucosylceramide. Similar results were obtained for C10-Cer. In the lower-dose C16-Cer experiments, most of the precursor was degraded, whereas at high-dose concentrations the precursor remained un-metabolized. Using this method, we demonstrate that ceramides with different chain lengths clearly exhibit varying rates of cellular uptake. The cellular fate of the externally delivered ceramides are clearly connected to their rate of incorporation and their subsequent effects on cell viability may be in part determined by their chain length.
Introduction
Sphingolipids are a major class of lipids that are ubiquitously present in the membranes of eukaryotes, where they function as important structural components and also exhibit important roles as bioactive molecules. Ceramide (Cer) has emerged as a central molecule in the sphingolipid metabolism, by serving as a precursor for all complex sphingolipids and displaying its involvement in a variety of cellular processes, including cell growth, signalling, proliferation, differentiation and apoptosis [1] [2] [3] [4] [5] . De novo synthesis of ceramide begins at the endoplasmatic reticulum, with a process that yields the long-chain amino-alcohol base, dihydrosphingosine. The dihydrosphingosine base is further modified by the addition of an acyl group by a ceramide synthase, yielding dihydroceramide. Introduction of a trans double bond between carbons 4 and 5 on the amino-alcohol base gives rise to ceramide [6] [7] [8] . Degradation
Here we have analysed the uptake of radiolabeled C6-Cer, C10-Cer and C16-Cer in complex with CholPC by HeLa cells. In addition, we analysed the cellular metabolism of the incorporated ceramides and assessed how the different Cer/CholPC formulations affect cell viability. We found that long-chain ceramides can be introduced to cells when complexed to CholPC. We demonstrate that ceramides with different chain lengths exhibit different rates of cellular uptake. The cellular fate of the delivered ceramides, and their subsequent effects on cell viability, strongly correlates with their rate of incorporation.
Materials and Methods

Material
All chemical reagents were of analytical grade or higher. Lipid standards where from Avanti Polar Lipids (Alabaster, USA) or Matreya LLC (Pleasant Gap, USA). Cholesteryl phosphocholine (CholPC) was synthesized as described by Lönnfors et al. [38] , or obtained from Avanti Polar Lipids. D-erythro-sphingosine and hexanoic acid were purchased from Larodan (Malmö, Sweden). H]D-erythro-sphingosine (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) Ci/mmol) and [9] [10] 3 H]hexadecanoic acid Ci/mmol) were obtained from PerkinElmer (Waltham, MA, USA). Decanoic and hexadecanoic acids were obtained from Sigma-Aldrich (St. Louis, MO, USA). Organic solvents were from Rathburn Chemicals Ltd (Walkerburn Scotland). HeLa cells (ATCC CCL-2, LGC Standards) were cultured in Dulbecco's Modified Eagle's medium (DMEM, Sigma-Aldrich) supplemented with penicillin (50 U/ml), streptomycin (50 U/ml), 4 mM L-glutamine and 10% fetal calf serum (FCS, all from Sigma-Aldrich) prior to the experiments. Chloroquine and ceranib-2 were purchased from Sigma-Aldrich and fumonisin B1 was purchased from Enzo Life Sciences (Farmingdale, NY, USA). H]D-erythro-sphingosine and hexanoic, decanoic and hexadecanoic acids, respectively, using N,N'-dicyclohexylcarbodiimide and triethylamine as catalysts [42] . [ 3 H]palmitoyl ceramide (C16-Cer) was prepared from sphingosine and [9] [10] 3 H]hexadecanoic acid, using N,N'-dicyclohexylcarbodiimide and triethylamine as catalysts [42] . The products were purified by preparative HPLC on a C18 phase, using methanol as solvent. Purity was assessed by analytical HPLC, and molecular identity by ESI-MS.
Synthesis of [ 3 H]-labeled ceramides
Preparation of ceramide-cholesterol phosphocholine bilayers
CholPC and ceramide were kept in hexane-isopropanol (3:2 by volume) solutions and stored at -20°C until used. Cer/CholPC complexes of desired concentration were prepared from the stock solutions. The appropriate amount of each lipid was dried under nitrogen in a glass tube, redissolved in chloroform to ensure proper lipid mixing and dried again. The dehydrated lipid film was then hydrated in PBS, pH 7.4, at 55°C for 20 minutes and then sonicated for 5 minutes in a FinnSonic M3 bath sonicator (FinnSonic Oy, Lahti, Finland) at the same temperature. The solution was further sonicated for 10 minutes using a Branson 250 probe sonifier at room temperature (Emerson Industrial Automation, St. Louis, MO, USA). The resulting clear solution was then immediately centrifuged at 12 000 rpm for 10 minutes using a table top microfuge, to remove titanium probe particles and any undispersed lipids. The solution was transferred to a glass tube and kept at RT and used within 1 h. Prior to use, the ceramide concentration in the solution was re-calculated based on the specific activity of the radiolabeled ceramide.
Labeling of cells, lipid and protein extraction
HeLa cells were cultured until 90% confluence before the start of each treatment. The previously prepared Cer/CholPC stock solution was added to DMEM supplemented with L-glutamine, antibiotics and 10% FCS, to achieve the desired concentration of ceramide. The ceramide concentration in the growth medium was verified by measuring the total radioactivity in solution. HeLa cells were washed twice in PBS, pH 7.4, and then exposed to the growth medium containing the Cer/CholPC complex. After treatment, the cells were washed twice in PBS and the cell dishes were dried to completion in a fume hood. The total lipids were extracted directly from the cell dishes using hexane-isopropanol (3:2 by volume). The extracted lipids were transferred to glass tubes and dried under a stream of nitrogen. The dried lipids were stored at -20°C until analysed. After lipid extraction, the cellular proteins were extracted with 0.1 M NaOH and the protein content was analysed by the Lowry method [43] . All cellular treatments were done in the presence of 10% FCS.
Identification and quantification of lipid species with HPTLC
The dried lipids were redissolved in hexane-isopropanol (3:2 by volume) and analysed on HPTLC plates using a solvent system consisting of chloroform:methanol:acetone:acetic acid: water (10:2:4:2:1). The different lipids were identified by standards, run in parallel with the samples. Glycosphingolipid (GSL) migration was visualized using orcinol spray (0.2% orcinol in a 20% H 2 SO 4 solution) and heating the plate on 120°C for 5 minutes. For the other lipids, subsequent iodine or cupric-acid staining was used for visualization. The marked silica spots were scraped into Optiphase 'Hi phase' scintillation fluid (PerkinElmer-Wallac, Turku, Finland) and the radioactivity was measured using a liquid scintillation counter (PerkinElmerWallac, Turku, Finland). The counts per minute (cpm) obtained were either normalized to the total protein content for each respective sample, or presented as a percentage of the total signal per sample.
Cell viability assay
A resazurin reduction assay (alarmaBlue, Life Technologies) was used to investigate cytotoxicity of C6-Cer, C10-Cer, and C16-Cer towards HeLa cells. The assay is based on the reduction of resazurin to the fluorescent molecule resorufin by viable cells. Nonviable cells lose their metabolic capability to reduce resazurin and no fluorescent resorufin is formed. HeLa cells were seeded to 50000 cells per well in a 24-well plate and were allowed to adhere and grow for 24h to a confluence of about 50%. The cells were treated for 22 hours with the different ceramides, cholesterol or PBS-vehicle. After the 22-hour incubation, the reazurin conversion assay was performed according to the manufacturer's instruction. The fluorescence was measured by a Varioskan Flash Multimode Reader (Thermo Scientific) using an excitation wavelength of 560 nm and an emission wavelength of 590 nm. Each experiment was performed at least 3 times, with 4 replicates each.
Dot blot analysis of C6-and C10-GlcCer
High-dose C6-and C10-GlcCer (50 μM and 100 μM, respectively) treated samples were analysed by HPTLC as described above. The HPTLC plate was stained by iodine vapour, and the lipid spots corresponding C6-and C10-GlcCer were scraped into glass tubes. The lipids were extracted from the scraped silica using chloroform-methanol (2:1 by volume) and dried under a nitrogen stream. The dried lipids were redissolved in hexane-isopropanol (3:2 by volume) and appropriate amounts were dotted onto a nitrocellulose membrane, alongside GlcCer and GalCer standards (2 nmol/dot). The lipids were visualized by immunoblotting, using commercial rabbit anti-GlcCer and rabbit anti-GalCer antibodies (Glycobiotech GmbH), a HRP-conjugated anti-rabbit secondary antibody (Thermo Scientific) and enhanced chemiluminescence detection (SuperSignal West Femto Maximum Sensitivity Substrate, Thermo Scientific).
Statistical Analysis
Conventional statistical analysis was performed to calculate mean values and standard errors of the mean. Differences between data points were tested for significance using Student's t-test for unpaired observations. Results are presented as means of at least three individual measurements with SEM.
Results
Cellular uptake and fate of [ Previously, Sukumaran and co-workers analysed whether C6-Cer could be introduced into cells in a solvent-free manner, by complexation with CholPC in vesicles [41] . They showed that C6-Cer in complex with CholPC resulted in a more dramatic apoptotic effect, compared to C6-Cer that was dissolved in DMSO and introduced by dispersion into the growth medium, demonstrating that the Cer/CholPC formulation appears to be superior to previous solvent delivery approaches. Here, we expand upon the methodology, and analyse the incorporation of longer-chain ceramides (C10-Cer and C16-Cer) into HeLa cells, using the same complexation approach (Fig 1) .
To measure the cellular uptake of the different ceramides, HeLa cells were subjected to 50 μM of the various chain length, [ 3 H]sphingosine labeled ceramides, complexed with CholPC in a 1:1 molar ratio. The total radiolabel uptake was analysed after 1, 3, 6 and 24 hours (Fig 2A) . Next we examined whether ceramides that are introduced to HeLa cells are metabolized to other sphingolipid classes. Cells were treated as described above (50 μM, 3, 6 and 24 h), whereafter total lipids were extracted and analysed using HPTLC and scintillation counting. S1 Fig  shows a representative HPTLC plate visualized using orcinol spray and subsequent cupric acid staining. The boxed regions correspond to the different lipids that were scraped off the plate (dashed lines represent "Other"). Fig 3 shows the quantified radioactivity in the different lipid species analysed, where each lipid is presented as a percentage of the total radioactivity in the sample (total in lane). As can be seen, the incorporated ceramide is metabolized and the radioactive label is distributed into other sphingolipids as a function of time. In the case of [ 3 H] C6-Cer (Fig 3A) , at 24 hours, over 40% of the radioactive signal could be found in the simple GSLs, i.e. glucosylceramide (GlcCer) and galactosylceramide (GalCer). However, for [ 3 H] C10-Cer ( Fig 3B) and [ 3 H]C16-Cer (Fig 3C) , the conversion favoured SM over simple GSLs.
Metabolic fate of exogenous ceramide is affected by the rate of incorporation
From the results presented in Fig 2, it is evident that the rate of incorporation was different between the varying ceramides. The short [ 3 H]C6-Cer had the most rapid uptake and was the only precursor which resulted in a large portion of the signal to be found in the simple GSLs after a 24 hour treatment ( Fig 3A) . Cancerous cells in culture have been shown to rapidly convert C6-Cer to either C6-SM or C6-GlcCer [44] . In some cancer cells the conversion route is determined by the initial C6-Cer concentration in the culture medium, where lower concentrations facilitate conversion to SM and higher concentrations result in conversion to GlcCer [44] . We therefore decided to analyse whether treating (Fig 5A and 5B) . Suitable ceramide concentrations were estimated based on the incorporation rates in Fig 2, and from previous works in the literature [44] . As expected, a low-dose treatment with [ 3 H]C6-Cer favoured conversion to SM (Fig 4A, grey bars) , whereas a higher concentrations yielded increasing signals in C6-GlcCer (Fig 4A, red, C10-Cer (Fig 4B) . Interestingly, a higher-dose treatment with [ 3 H]C16-Cer, did not result in a marked increase of signal to be found in the simple GSLs (Fig 5A) . Instead, the majority of the signal remained in ceramide. This was evident for both the sphingosine (Fig 5A) and the palmitic acid (Fig 5B) radiolabel resided on the acyl chain of the ceramide, a significant portion of the radioactivity could be found in the glycerophospholipids (Fig 5B) . This suggests that [ 3 H]C16-Cer is subject to significant degradation when delivered from Cer/CholPC complexes. This issue was further addressed by using the ceramidase inhibitor ceranib-2 and the lysosome inhibitor chloroquine. We found that when HeLa cells were treated with ceranib-2 (20 μM) or chloroquine (20 μM) and subsequently loaded with [ In the higher-dose experiments, both C6-GlcCer and C10-GlcCer were clearly distinguishable from the longer-chain GlcCer-and GalCer-standards on the HPTLC plate, as indicated by orcinol staining (S4A Fig). The C6-GlcCer and C10-GlcCer lipid spots were experimentally validated by immunodetection using rabbit anti-GlcCer and rabbit anti-GalCer antibodies (S4B Fig). Cell viability in response to increasing concentration of C6-, C10-and C16-Cer/CholPC formulations As was previously reported, complexation of C6-Cer with CholPC gave rise to higher apoptotic effects and more drastic inhibition of cell growth in HeLa and FRTL-5 cells, when compared to DMSO-solubilised C6-Cer treatment [41] . Lower-dose treatments using the various ceramides did not result in noticeable cell detachment or morphological changes (visual observation, data not shown), whereas respective high-dose treatments did. We therefore investigated what effects the treatments had on cell viability, using a commercial reazurin-conversion assay.
Cells were treated with varying doses of cholesterol (as a control), C6-Cer, C10-Cer or C16-Cer (25-200 μM) in complex with CholPC (Fig 6) . The cell viability of each sample was normalized to respective vehicle (PBS) treated controls. The treatments were carried out for 22 hours, where after cell viability was assayed. The results show that all ceramide treatments had a dose-dependent effect on cell viability, where the C6-Cer/CholPC formulation was the most effective at decreasing viability. The cholesterol/CholPC vesicles, even at higher doses (200 μM), did not significantly affect cell proliferation. As shown previously, the incorporation speed of the three different ceramide species varied significantly (Fig 2) . C16-Cer, despite exhibiting an incorporation rate of only 5% when compared to C6-Cer, was still able to induce a marked reduction in cell viability at a concentration of 200 μM
Discussion
Ceramides are important bioactive molecules that are implicated in many cellular processes, including cell growth, senescence, necrosis, differentiation, proliferation and apoptosis [1] [2] [3] [4] [5] . The study of ceramides and their function has been hampered by the molecule's inherent physical attributes. Ceramide is highly hydrophobic and therefore does not efficiently transfer to cells when dispersed in aqueous growth medium. Instead, non-physiological short-chain ceramides have been used extensively to study the effects of ceramide in cells, due to their watersoluble nature. Cyclodextrins have been utilized for both the loading and the depletion of cholesterol in cellular studies [45, 46] . However, ceramides do not seem to favour the formation of water-soluble complexes with cyclodextrins, and therefore cyclodextrins offer only a limited solution for ceramide delivery [47] . Liposomal complexes of ceramides have been previously used to deliver C16-Cer into cells [48] . While high ceramide content liposomes (up to 50 mol% ceramide) were successfully produced, cells with enhanced liposome endocytosis had to be utilized for efficient uptake and maximal cellular response.
We have previously shown that C6-Cer and C16-Cer can form apparently stable, fluid bilayers with CholPC in a 1:1 molar ratio [38] . We previously also demonstrated that C6-Cer can be introduced to cells efficiently when complexed with CholPC and that the C6-Cer/CholPC formulation was superior to the C6-Cer/DMSO formulation in all cellular responses studied [41] . In the present study, we demonstrate that the same methodology of complexation can be utilized for introducing longer-chain C10-Cer and C16-Cer into cells. In addition, we show that the rate of the uptake seems to be a defining factor in how the cells metabolize the introduced ceramide.
Our results indicate that all three ceramides could successfully be delivered to cells by virtue of their CholPC formulations. The short-chain C6-Cer had the highest incorporation rate, followed by the C10-Cer and the C16-Cer, respectively. Sukumaran and co-workers previously suggested that the method of C6-ceramide uptake mainly takes place through monomeric exchange between the ceramide/CholPC bilayer and the plasma membrane [41] . This suggestion is supported by the results presented in this study. The acyl chain length of lipids correlate with their transfer efficiency between membrane structures [49, 50] . Longer-chain ceramides should therefore transfer between membrane structures more slowly than shorter-chain ones. However, fusion of Cer/CholPC vesicles with the plasma membrane, and subsequent internalization, cannot be completely ruled out as an uptake method, since it was previously reported that CholPC also was internalized by the cells [41] .
The metabolism of the externally delivered ceramide was not studied previously [41] . We therefore decided to analyse and compare the cellular fates of the different ceramides. At concentrations of 50 μM, there were marked differences in how the different ceramides ([ 3 H]-labeled in the sphingosine backbone or in the (B) palmitic acid portion. After 24 h of ceramide uptake the total lipids were extracted and analysed by HPTLC. "Start" and "Front" refer to the labeled lipids remaining on the application spot, or that were eluted along the solvent front, "Other" refers to the traces of radiolabeled lipids between the identified spots (see S1 Fig) . The data is from at least three different experiments. In some cancer cells, C6-Cer metabolism has been shown to be subject to the initial C6-Cer concentrations the cells are exposed to [44] . Lower concentrations seem to facilitate conversion of C6-Cer to C6-SM, whereas higher concentrations favour conversion to C6-GlcCer. Since the longer-chain [ proliferative effects on HeLa cells, when compared to C10-Cer. This is evident when comparing the effects the two ceramides has on cell viability, when the rate of incorporation (based on total uptake after 3 h) has been accounted for. C6-Cer has a stronger effect on HeLa cell viability, even when C10-Cer has a higher incorporation level (25 μM C6-Cer versus 100 μM C10-Cer). It is also interesting to note that the effects that a 200 μM C16-Cer treatment had on the cell viability were comparable to that of a 100 μM of C10-Cer, even when C10-Cer uptake was higher than that of C16-Cer. One explanation for the observed phenomenon may lie in how the metabolism of C16-Cer (or rather, the lack thereof) in HeLa cells occurs. In high-dose treatments with [ 3 H]C16-Cer (200 μM), most of the signal remained as ceramide after 24 hours. In the comparable C6-Cer and C10-Cer experiments, the cells converted the ceramide to GlcCer. Glycosylation of ceramide may be a method by which the cell is able to suppress the anti-proliferative effects of high doses of externally introduced ceramides. Both GlcCersynthase inhibitors, as well as P-gp antagonists, have been shown to enhance the ceramideinduced apoptotic effects when co-administered with short-chain ceramides [44, 58, 59] . Presumably, when the synthesis of GlcCer is blocked, the higher accumulation of ceramides also leads to higher apoptotic effects. Why we, in this study, see a glycosylation of the shorter-chain C6-Cer and C10-Cer, but not of C16-Cer, is an interesting question. Based on the incorporation rates, it is possible that the rate of C16-Cer uptake simply is not fast enough for the glycosylation response to occur. Another possibility that cannot be ruled out is that CholPC may affect how the cells metabolize ceramide. The fact that cholesterol/CholPC vesicles did not have a significant effect on cell viability, even at high concentrations (200 μM), does not exclude the possibility of combinational effects from high levels of ceramide and CholPC. At high concentrations, CholPC may interfere with how the cells process ceramide, inhibiting their glycosylation, and subsequently leading to higher apoptotic effects. This would also explain the lower rates of glycosylation observed in the 200 μM C10-Cer incorporation experiments, when comparing to the corresponding 100 μM C10-Cer experiments.
Conclusions
The ceramides are a varied molecular species. Distinct enzymes control the chain lengths and saturation of the ceramides, as well as the introduction of functional groups [18, [60] [61] [62] [63] [64] . More than 100 distinct mammalian ceramides are detectable using current LC-MS/MS technologies [65] . Because ceramides also exhibit high degrees of compartmentalization in cells, it is plausible that different ceramides may influence different signalling pathways [17] [18] [19] [20] 66] . In the present study, we have shown that C6-Cer, C10-Cer and C16-Cer can be introduced into cells by complexation with CholPC. Using this method, we demonstrate that ceramides with different chain lengths clearly exhibit varying rates of cellular uptake. The cellular fate of the externally delivered ceramides, and their subsequent effects on cell viability, may be in part determined by their chain length. Our results suggest that C6-Cer displays an intrinsically stronger anti-proliferative effect when compared to C10-Cer, even when C10-Cer incorporation is equal to, or greater than that of C6-Cer. As the ceramide concentration is increased, the cellular fate of the different ceramides is clearly altered. Both C6-Cer and C10-Cer are glycosylated in HeLa cells at high degrees of cellular uptake. Due to its much slower incorporation rate compared to C6-Cer and C10-Cer, we were unable to determine whether C16-Cer also undergoes such glycosylation. Glycosylation is perhaps a general mechanism by which cells dispose of high amounts of ceramide. A further metabolism of the exogenously added ceramides into GlcCer may obviously also plays a role in the cell viability. While CholPC and cholesterol did not by themselves result in any significant alteration of cell viability, it cannot be excluded that there may be combinational effects between high levels of ceramide and CholPC, affecting cell viability as well as altering how externally delivered ceramide is metabolized. It is also important to note that externally administered ceramides may give rise to significantly different cellular effects, when compared to their endogenously generated counterparts. The dot blot was performed to verify that the lipid spots observed in the high-dose C6-and C10-Cer treatments were GlcCer. The HPTLC plate was stained using iodine, and the spots corresponding to C6-and C10-GlcCer were scraped into glass tubes. Lipids were extracted from the silica and absorbed onto a nitrocellulose membrane. Rabbit anti-GlcCer and rabbit anti-GalCer antibodies were used to detect and verify the lipids on the membrane. Commercial standards of GlcCer and GalCer were used as positive and negative controls. The dot blot analysis was repeated twice with identical results.
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